Aim: Cost–effectiveness (CE) analysis of empagliflozin+standard of care (SoC) compared
with SoC and liraglutide+SoC, in patients with Type II diabetes and established cardiovascular
disease, was conducted using evidence from cardiovascular outcomes ...